Protagonist Therapeutics, Inc. (PTGX) Financials
PTGX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2024-03-31 | 629.3 million | 68.8 million |
| 2023-12-31 | 358.0 million | 21.3 million |
| 2023-09-30 | 330.0 million | 27.9 million |
| 2023-06-30 | 320.5 million | 26.4 million |
PTGX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2024-03-31 | -27.7 million | 9.4 million |
| 2023-12-31 | 16.9 million | 6.6 million |
| 2023-09-30 | -27.0 million | 6.8 million |
| 2023-06-30 | -26.4 million | 8.3 million |
PTGX Net Income
No data available :(
PTGX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2024-03-31 | 322.6 million | - | 462000 |
| 2023-12-31 | 341.6 million | - | 1.1 million |
| 2023-09-30 | 322.7 million | - | 1.8 million |
| 2023-06-30 | 313.4 million | - | 2.4 million |
PTGX Shares Outstanding
PTGX Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2024-03-31 | 242000 | 33.7 million | 14.9 million | -820000 |
| 2023-12-31 | 19000 | 28.9 million | 8.1 million | - |
| 2023-09-30 | 404000 | 30.7 million | 7.7 million | - |
| 2023-06-30 | 176000 | 33.2 million | 9.2 million | - |
PTGX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2024-03-31 | 255.0 million | 820000 |
| 2023-12-31 | 60.0 million | 832000 |
| 2023-09-30 | - | 827000 |
| 2023-06-30 | - | 821000 |
PTGX
Price: $30.74
52 week price:
Earnings Per Share: 2.54 USD
P/E Ratio: -9.97
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 966400
Ebitda: -4.9 millionMarket Capitalization: 1.9 billion